<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36369966</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Cancer science</Title><ISOAbbreviation>Cancer Sci</ISOAbbreviation></Journal><ArticleTitle>Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma.</ArticleTitle><Pagination><StartPage>1095</StartPage><EndPage>1107</EndPage><MedlinePgn>1095-1107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.15645</ELocationID><Abstract><AbstractText>Malignant pleural mesothelioma (MPM) is an aggressive solid cancer with a poor prognosis, whereas coxsackievirus A11 (CVA11) is a potential oncolytic virus for cancer treatment. We here investigated the oncolytic activity of CVA11 with human MPM cell lines. CVA11 infection was cytotoxic in all six MPM cell lines examined and showed no or minimal cytotoxicity toward normal human normal cell lines. MPM cells with a higher surface level of intercellular adhesion molecule-1 (ICAM-1) expression tended to be more susceptible to CVA11-induced cytotoxicity, and a neutralizing antibody to ICAM-1 attenuated such cytotoxicity. CVA11 infection activated signaling by Akt and extracellular signal-regulated kinase (ERK) pathways, and inhibitors of such signaling also abrogated CVA11-mediated cytotoxicity. Furthermore, CVA11 infection-triggered multiple modes of tumor cell death including apoptosis, pyroptosis, and necroptosis, and such death was accompanied by the release or exposure of the proinflammatory cytokine interleukin-1β and damage-associated molecular patterns such as calreticulin, high-mobility group box-1, annexin A1, and heat shock protein 70, which are hallmarks of immunogenic cell death. Notably, in vivo treatment of human MPM xenografts with intratumoral CVA11 injection resulted in significant suppression of tumor growth in SCID mice, and all mice infected with CVA11 showed no significant change in body weight. Our findings collectively suggest that the oncolytic activity of CVA11 for MPM is dependent on ICAM-1 as a virus receptor, as well as on Akt and ERK signaling, and that oncolytic virotherapy with CVA11 is a promising treatment modality with immunostimulatory activity for human MPM.</AbstractText><CopyrightInformation>© 2022 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okamura</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8071-8797</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikematsu</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, National Hospital Organization Omuta Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoneshima</LastName><ForeName>Yasuto</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0053-7241</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwama</LastName><ForeName>Eiji</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8252-290X</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Isamu</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>A238</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant><Grant><Agency>Juntendo University</Agency><Country /></Grant><Grant><Agency>Center for Clinical and Translational Research</Agency><Country /></Grant><Grant><Agency>Kyushu University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Sci</MedlineTA><NlmUniqueID>101168776</NlmUniqueID><ISSNLinking>1347-9032</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>126547-89-5</RegistryNumber><NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086002" MajorTopicYN="Y">Mesothelioma, Malignant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008654" MajorTopicYN="Y">Mesothelioma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010997" MajorTopicYN="Y">Pleural Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">immunogenic cell death</Keyword><Keyword MajorTopicYN="N">intercellular adhesion molecule-1</Keyword><Keyword MajorTopicYN="N">mesothelioma</Keyword><Keyword MajorTopicYN="N">oncolytic virotherapy</Keyword></KeywordList><CoiStatement>This work was supported by the Translational Research Network Program of AMED (grant number A238); Hiroyuki Inoue receives a remuneration from Jocavio Inc. as an adviser, owns shares of stock in Jocavio Inc., and holds a patent on CVA11 [PCT/UP2O13A061686, PCT/JP2013/061686]; The other authors have no conflict of interest; all authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36369966</ArticleId><ArticleId IdType="pmc">PMC9986072</ArticleId><ArticleId IdType="doi">10.1111/cas.15645</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475‐488.</Citation><ArticleIdList><ArticleId IdType="pubmed">28740119</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D, Yu Y, Mei Q, et al. Advances in immunotherapy of malignant pleural mesothelioma. Onco Targets Ther. 2021;14:4477‐4484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8374846</ArticleId><ArticleId IdType="pubmed">34429612</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas P, Scherpereel A, Nowak AK, et al. First‐line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open‐label, phase 3 trial. Lancet. 2021;397:375‐386.</Citation><ArticleIdList><ArticleId IdType="pubmed">33485464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene Laherparepvec (T‐VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18:1‐15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8977104</ArticleId><ArticleId IdType="pubmed">27988837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogue GP, Huntley CC, Hall TC. Common replication strategies emerging from the study of diverse groups of positive‐strand RNA viruses. Arch Virol Suppl. 1994;9:181‐194.</Citation><ArticleIdList><ArticleId IdType="pubmed">8032249</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto A, Hirata R, Ishimoto K, et al. An outbreak of hand‐foot‐and‐mouth disease mimicking chicken pox, with a frequent association of onychomadesis in Japan in 2009: a new phenotype caused by coxsackievirus A6. Eur J Dermatol. 2014;24:103‐104.</Citation><ArticleIdList><ArticleId IdType="pubmed">24334231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Ogata H, Takishima Y, et al. A novel combination therapy for human Oxaliplatin‐resistant colorectal cancer using Oxaliplatin and Coxsackievirus A11. Anticancer Res. 2018;38:6121‐6126.</Citation><ArticleIdList><ArticleId IdType="pubmed">30396927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV‐A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5:e75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonpolio enterovirus and human parechovirus surveillance‑United States, 2006–2008. MMWR Morb Mortal Wkly Rep. 2010;59:1577‐1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">21150865</ArticleId></ArticleIdList></Reference><Reference><Citation>Usami N, Fukui T, Kondo M, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97:387‐394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11158456</ArticleId><ArticleId IdType="pubmed">16630136</ArticleId></ArticleIdList></Reference><Reference><Citation>Darling AJ, Boose JA, Spaltro J. Virus assay methods: accuracy and validation. Biologicals. 1998;26:105‐110.</Citation><ArticleIdList><ArticleId IdType="pubmed">9811514</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482‐491.</Citation><ArticleIdList><ArticleId IdType="pubmed">19881547</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X, Nakamura T, Okazaki T, et al. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild‐type N, P, L genes on human renal cell carcinoma. Mol Ther. 2010;18:544‐551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839424</ArticleId><ArticleId IdType="pubmed">20051938</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren DR, Dorahy DJ, Greive SJ, Burns GF, Barry RD. Mouse cells expressing human intercellular adhesion molecule‐1 are susceptible to infection by coxsackievirus A21. J Virol. 1997;71:785‐789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191118</ArticleId><ArticleId IdType="pubmed">8985417</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. Coxsackievirus A21 binds to decay‐accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol. 1997;71:4736‐4743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191695</ArticleId><ArticleId IdType="pubmed">9151867</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S, Inoue H, Nakamura T, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72:2609‐2621.</Citation><ArticleIdList><ArticleId IdType="pubmed">22461509</ArticleId></ArticleIdList></Reference><Reference><Citation>Esfandiarei M, Luo H, Yanagawa B, et al. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol. 2004;78:4289‐4298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC374262</ArticleId><ArticleId IdType="pubmed">15047842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Li X, Guo D, et al. Lipid raft‐associated PI3K/Akt/SREBP1 signaling regulates coxsackievirus A16 (CA16) replication. Vet Microbiol. 2021;252:108921.</Citation><ArticleIdList><ArticleId IdType="pubmed">33191001</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989763</ArticleId><ArticleId IdType="pubmed">24782985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51‐72.</Citation><ArticleIdList><ArticleId IdType="pubmed">23157435</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8, 1‐21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7064135</ArticleId><ArticleId IdType="pubmed">32209603</ArticleId></ArticleIdList></Reference><Reference><Citation>Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860‐875.</Citation><ArticleIdList><ArticleId IdType="pubmed">23151605</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014;21:39‐49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857623</ArticleId><ArticleId IdType="pubmed">23832118</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death −1 (PD‐1) and ligand (PD‐L1): a new era in cancer active immunotherapy. Pharmacol Ther. 2019;194:84‐106.</Citation><ArticleIdList><ArticleId IdType="pubmed">30268773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulli T, Koskimies P, Hyypiä T. Molecular comparison of coxsackie a virus serotypes. Virology. 1995;212:30‐38.</Citation><ArticleIdList><ArticleId IdType="pubmed">7676647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotteas EA, Boulas P, Gkiozos I, Tsagkouli S, Tsoukalas G, Syrigos KN. The intercellular cell adhesion molecule‐1 (icam‐1) in lung cancer: implications for disease progression and prognosis. Anticancer Res. 2014;34:4665‐4672.</Citation><ArticleIdList><ArticleId IdType="pubmed">25202042</ArticleId></ArticleIdList></Reference><Reference><Citation>Roland CL, Harken AH, Sarr MG, Barnett CC Jr. ICAM‐1 expression determines malignant potential of cancer. Surgery. 2007;141:705‐707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17560245</ArticleId></ArticleIdList></Reference><Reference><Citation>Bui TM, Wiesolek HL, Sumagin R. ICAM‐1: a master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020;108:787‐799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7977775</ArticleId><ArticleId IdType="pubmed">32182390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruco LP, de Laat PA, Matteucci C, et al. Expression of ICAM‐1 and VCAM‐1 in human malignant mesothelioma. J Pathol. 1996;179:266‐271.</Citation><ArticleIdList><ArticleId IdType="pubmed">8774481</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261‐1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756685</ArticleId><ArticleId IdType="pubmed">17604717</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts PJ, Der CJ. Targeting the Raf‐MEK‐ERK mitogen‐activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291‐3310.</Citation><ArticleIdList><ArticleId IdType="pubmed">17496923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebolt‐Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5:810‐816.</Citation><ArticleIdList><ArticleId IdType="pubmed">10395327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41−/43−kDa mitogen‐activated protein kinase signaling pathway in human tumors. Oncogene. 1999;18:813‐822.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989833</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo M, Gerbase MW, Curran J, Pache JC. Phosphorylated extracellular signal‐regulated kinases are significantly increased in malignant mesothelioma. J Histochem Cytochem. 2006;54:855‐861.</Citation><ArticleIdList><ArticleId IdType="pubmed">16517979</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Hollingsworth LRt, Wu H. Mechanism and Regulation of Gasdermin‐Mediated Cell Death. Cold Spring Harb Perspect Biol. 2020;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050592</ArticleId><ArticleId IdType="pubmed">31451512</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian F, Yao J, Yan M, et al. 5‐Aminolevulinic acid‐mediated Sonodynamic therapy inhibits RIPK1/RIPK3‐dependent necroptosis in THP‐1‐derived foam cells. Sci Rep. 2016;6:21992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766406</ArticleId><ArticleId IdType="pubmed">26911899</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsch M, Günther SD, Schwarzer R, et al. Caspase‐8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575:683‐687.</Citation><ArticleIdList><ArticleId IdType="pubmed">31748744</ArticleId></ArticleIdList></Reference><Reference><Citation>Malireddi RKS, Tweedell RE, Kanneganti TD. PANoptosis components, regulation, and implications. Aging (Albany NY). 2020;12:11163‐11164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7343493</ArticleId><ArticleId IdType="pubmed">32575071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Fan Z, Luo G, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18:100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6532150</ArticleId><ArticleId IdType="pubmed">31122251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, Tian S, Pan Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121:109595.</Citation><ArticleIdList><ArticleId IdType="pubmed">31710896</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro‐cancer or pro‐"host"? Cell Death Dis. 2019;10:650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733901</ArticleId><ArticleId IdType="pubmed">31501419</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz RM, Galivo F, Kottke T, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 2007;67:2840‐2848.</Citation><ArticleIdList><ArticleId IdType="pubmed">17363607</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothey A, Heistermann P, Philippou S, Voigtmann R. Serum levels of soluble intercellular adhesion molecule‐1 (ICAM‐1, CD54) in patients with non‐small‐cell lung cancer: correlation with histological expression of ICAM‐1 and tumour stage. Br J Cancer. 1998;77:801‐807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2149953</ArticleId><ArticleId IdType="pubmed">9514061</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16:3100‐3104.</Citation><ArticleIdList><ArticleId IdType="pubmed">20421432</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone DP, Reck M, Paz‐Ares L, et al. First‐line Nivolumab in stage IV or recurrent non‐small‐cell lung cancer. N Engl J Med. 2017;376:2415‐2426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487310</ArticleId><ArticleId IdType="pubmed">28636851</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD‐1 blockade in non‐small cell lung cancer. Science. 2015;348:124‐128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993154</ArticleId><ArticleId IdType="pubmed">25765070</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell L, Swanner J, Jaime‐Ramirez AC, et al. PTEN expression by an oncolytic herpesvirus directs T‐cell mediated tumor clearance. Nat Commun. 2018;9:5006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6258708</ArticleId><ArticleId IdType="pubmed">30479334</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD‐L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378974</ArticleId><ArticleId IdType="pubmed">28345650</ArticleId></ArticleIdList></Reference><Reference><Citation>Eissa IR, Mukoyama N, Abdelmoneim M, et al. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8(+) PD‐1(−) tumor‐infiltrating T cells in PD‐L1‐enriched tumor microenvironment. Int J Cancer. 2021;149:214‐227.</Citation><ArticleIdList><ArticleId IdType="pubmed">33687756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamada M, Yura Y. Efficient delivery and replication of oncolytic virus for successful treatment of head and neck cancer. Int J Mol Sci. 2020;21:1‐22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7582277</ArticleId><ArticleId IdType="pubmed">32992948</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla B, Aguilera EA, Salazar L, Wootton SH, Kaewpoowat Q, Hasbun R. Aseptic meningitis in adults and children: diagnostic and management challenges. J Clin Virol. 2017;94:110‐114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581214</ArticleId><ArticleId IdType="pubmed">28806629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>